多西他赛＋奈达铂＋方克联合同步放疗治疗局部晚期食管癌临床观察  

作　　者：段宏燕[1] 李光[1] 

机构地区：[1]中国医科大学附属一院,辽宁沈阳110001

出　　处：《中国中医药咨讯》2010年第29期6-7,共2页

摘　　要：目的：观察多西他赛＋奈达铂＋方克联合同步放疗治疗局部晚期食管癌的疗效和不良反应。方法：对106例局部晚期食管癌随机分组为两组：化放疗组（A组），采用三维适形放疗，调强放疗同步TFP方案化疗4个周期。化疗用药多西他赛（国产艾素）50mg／m2，d1，静滴＋奈达铂60mg，d1-3，静滴＋方克1g，d1～3，静滴，放疗开始后第1、5、8、11周化疗；化疗同天放疗，采用三维适形放疗／调强放疗。单放组（B组）行单纯三维适形放疗／调强放疗。结果：化放疗组有效率87．5％，单纯放组有效率64％，化放疗组的有效率明显高于单放组（P〈0．05）；化放疗组1、2年生存率分别为82．1％、53．6％，单放组为56％、36％，化放疗组1、2年生存率明显高于单放组P〈0．05。结论：改良TFP方案联合同步放疗治疗局部晚期食管癌优于单纯放疗，可明显提高中晚期食管癌的疗效，放射性食管炎、骨髓抑制等毒副反应仍然偏高，但可耐受性，有一定治疗优势，值得在临床中进一步研究验证。Objective： To evaluate efficacy and toxicity of concurrent chemotherapy and radiotherapy for locally advanced esophageal carcinoma patients. Methods： One hundred and six cases were treated with docetaxel, nedaplain and fluorofur with concurrent radiotherapy for locally advanced esophageal cancer. A （ concurrent radiotherapy and chemotherapy, CCRT ） chemotherapy ： docetaxe 50mg/m2, dl, iv ＋ nedaplain 60mg, dl-3, iv ＋ fluorofur 1 g, d 1-3, iv, w 1,5,8,11; 3DCRT/IMRT ： 60-66Gy/7-7.5w. B （ only radiotherapy 3DCRT/IMRT ） 3DCRT/IMRT ： 60-66Gy/7-7.5w. Results： All of the patients finished the CCRT and 3DCRT/IMRT. In 56 patients of A, 87.5%（49/56） of the overall response rate was observed, In 50 patients of B, 64%（32/50） of the overall response rate was observed. Conclusion： docetaxel , nedaplain and fluorofur combined with concurrent radiotherapy for locally advanced esophageal cancer is effective and well-tolerated in patients with locally advanced esophageal cancer.

关 键 词：食管癌 多西他赛 奈达铂 方克 化学治疗 放射治疗 

分 类 号：R735.1[医药卫生—肿瘤]